Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25016
Abstract: Therapeutic complement inhibition by eculizumab has revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH) with a major impact on its natural history. Nevertheless, emerging unmet clinical needs may benefit from the development of novel complement… read more here.
Keywords: paroxysmal nocturnal; inhibition; nocturnal hemoglobinuria; complement inhibition ... See more keywords
Complement Inhibition for Geographic Atrophy: Review of Salient Functional Outcomes and Perspective.
Sign Up to like & getrecommendations! Published in 2023 at "Retina"
DOI: 10.1097/iae.0000000000003796
Abstract: PURPOSE To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. METHODS Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pegol, were evaluated… read more here.
Keywords: complement inhibition; geographic atrophy; autofluorescence; atrophy ... See more keywords
Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Nephrology and Hypertension"
DOI: 10.1097/mnh.0000000000000499
Abstract: Purpose of review Atypical hemolytic uremic syndrome (aHUS) is a diagnosis that has captured the interest of specialists across multiple fields. The hallmark features of aHUS are microangiopathic hemolysis and thrombocytopenia, which creates a diagnostic… read more here.
Keywords: complement inhibition; uremic syndrome; hemolytic uremic; atypical hemolytic ... See more keywords
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Sign Up to like & getrecommendations! Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.abo2341
Abstract: Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19… read more here.
Keywords: complement inhibition; severe covid; covid; inhibition severe ... See more keywords
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.202007-2778le
Abstract: potential for lung recruitment (as the recruitment-to-inflation ratio) in COVID-19 ARDS. The researchers found that lung recruitability was generally poor on the first day of observation but increased by alternating the prone and supine positions… read more here.
Keywords: complement inhibition; inhibition blocker; covid ards; consolidation ... See more keywords
Complement Inhibition in ANCA-Associated Vasculitis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.888816
Abstract: Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activation… read more here.
Keywords: associated vasculitis; inhibition anca; anca associated; complement inhibition ... See more keywords